MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 3, 2017--
Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will
present an overview of the company’s business at the 29th
Annual Piper Jaffray Healthcare Conference in New York.
The presentation is scheduled for 4:00pm ET on November 28, 2017, at the
Lotte New York Palace in New York City.
A replay of the presentation will be available via the investors section
of the company’s website at www.intersectENT.com.
The webcast replay will be archived for approximately one month.
About Intersect ENT®
Intersect ENT is dedicated to transforming the landscape of care for
patients with ear, nose and throat conditions. The company’s PROPEL®
family of dissolvable steroid releasing sinus implants are clinically
proven to improve outcomes for chronic sinusitis patients undergoing
sinus surgery. In addition, Intersect ENT is continuing to expand its
portfolio of products based on the company’s unique localized steroid
releasing technology and is committed to broadening patient access to
less invasive and more cost effective care.
For additional information on the company or the products including
risks and benefits please visit www.IntersectENT.com.
Intersect ENT® and PROPEL® are registered
trademarks and SINUVA is a trademark of Intersect ENT, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171103005022/en/
Source: Intersect ENT, Inc.
Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105